Clinical Trial Update: A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Eloralintide (LY3841136) for obstructive sleep apnea in adults with obesity or overweight; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Obstructive Sleep Apnea

Drugs mentioned

• Eloralintide (LY3841136)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Sleep Apnea, Obstructive, Obesity | Phase 3 | Status: RECRUITING